DaVita Inc. (DVA)
| Market Cap | 11.48B +16.5% |
| Revenue (ttm) | 14.01B +6.4% |
| Net Income | 847.48M +1.3% |
| EPS | 12.11 +18.7% |
| Shares Out | 63.77M |
| PE Ratio | 15.32 |
| Forward PE | 11.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 473,725 |
| Open | 180.97 |
| Previous Close | 183.99 |
| Day's Range | 179.95 - 184.13 |
| 52-Week Range | 101.00 - 247.49 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 218.43 (+21.31%) |
| Earnings Date | Oct 28, 2026 |
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]
Financial Performance
In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for DVA stock is "Buy." The 12-month stock price target is $218.43, which is an increase of 21.31% from the latest price.
News
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its una...
DaVita enters care pact with Humana for chronic kidney disease patients
DaVita (DVA) announced a new value-based care agreement to deliver coordinated care to Humana (HUM) Medicare Advantage members with chronic kidney disease stages 3B-5. The company said, “Launched July...
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based ca...
DaVita price target lowered to $215 from $250 at Truist
Truist lowered the firm’s price target on DaVita (DVA) to $215 from $250.
DaVita upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Ryan Langston upgraded DaVita (DVA) to Buy from Hold with a price target of $220, up from $201. The firm cites the company’s improved long-term outlook the…
DaVita price target raised to $265 from $220 at Deutsche Bank
Deutsche Bank analyst Pito Chickering raised the firm’s price target on DaVita (DVA) to $265 from $220 and keeps a Buy rating on the shares.
DaVita price target raised to $170 from $145 at BofA
BofA analyst Kevin Fischbeck raised the firm’s price target on DaVita (DVA) to $170 from $145 and keeps an Underperform rating on the shares. The firm fine-tuned its estimates on…
DaVita price target raised to $224 from $218 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on DaVita (DVA) to $224 from $218 and keeps an Equal Weight rating on the shares post the Q2 report. The…
DaVita flags lower revenue per treatment, reaffirms annual forecast
DaVita said on Tuesday revenue per treatment was lower in the second quarter, blaming declining enrollments for dialysis treatments as patients dropped out of Obamacare plans following the end of pa...
DaVita Earnings Call Transcript: Q2 2026
Second quarter results met expectations with strong volume growth from improved mortality, offset by lower commercial mix and phosphate binder revenue. Full-year guidance is reaffirmed, with continued investment in clinical innovation and capital allocation discipline.
DaVita Earnings release: Q2 2026
DaVita released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
DaVita Quarterly report: Q2 2026
DaVita has published its Q2 2026 quarterly earnings report on August 4, 2026.
DaVita reports Q2 EPS $4.02, consensus $3.88
Reports Q2 revenue $3.554B, consensus $3.49B. “Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results,” said Javier Rodrigu...
DaVita sees FY26 adjusted EPS $14.10-$15.20, consensus $14.88
Sees FY26 Adjusted operating income $2.150B-$2.250B.
DaVita Inc. 2nd Quarter 2026 Results
DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had ...
DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m...
DaVita price target raised to $250 from $205 at Truist
Truist raised the firm’s price target on DaVita (DVA) to $250 from $205 and keeps a Hold rating on the shares as part of a broader research note previewing Q2…
DaVita price target raised to $270 from $235 at UBS
UBS raised the firm’s price target on DaVita (DVA) to $270 from $235 and keeps a Buy rating on the shares. DaVita remains on track to achieve its long-term goal…
DaVita price target raised to $218 from $194 at Barclays
Barclays raised the firm’s price target on DaVita (DVA) to $218 from $194 and keeps an Equal Weight rating on the shares. The firm adjusted targets among its U.S. healthcare…
DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals
Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities. DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitme...
DaVita Transcript: Bank of America Global Healthcare Conference 2026
Volume guidance was raised due to competitor clinic closures and improved mortality, with most benefits expected by mid-year. OI growth is supported by international and value-based care, while AI and clinical innovations are being pursued for future efficiency and patient outcomes.
DaVita price target raised to $201 from $144 at TD Cowen
TD Cowen raised the firm’s price target on DaVita (DVA) to $201 from $144 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…
DaVita price target raised to $205 from $158 at Truist
Truist raised the firm’s price target on DaVita (DVA) to $205 from $158 and keeps a Hold rating on the shares. The firm is raising its assumed multiple after the…
DaVita price target raised to $235 from $190 at UBS
UBS analyst AJ Rice raised the firm’s price target on DaVita (DVA) to $235 from $190 and keeps a Buy rating on the shares.
DaVita price target raised to $194 from $158 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on DaVita (DVA) to $194 from $158 and keeps an Equal Weight rating on the shares. The firm updated the company’s…